GlassScriptPhysician profile
Jamal Gerges Maatouk
NPI 1205016060
$47,432.39
in general payments reported to CMS, 2019-2025
43 companies · $1,852 in 2025
The $1,852 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,925 · 2021: $8,362 · 2022: $12K · 2023: $295 · 2024: $282 · 2025: $1,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.40 |
| Education | $128.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $44,682.12 | 2019-2025 | Jakafi |
| Novartis Pharmaceuticals Corporation | $514.08 | 2020-2025 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Daiichi Sankyo INC. | $181.66 | 2024-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $124.83 | 2022-2023 | Jaypirca, Retevmo, Verzenio |
| Regeneron Healthcare Solutions, INC. | $114.30 | 2025 | Libtayo |
| Intera Oncology, INC | $112.29 | 2025 | Intera |
| Merck Sharp & Dohme LLC | $106.51 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $105.36 | 2019-2025 | |
| Glaxosmithkline, LLC. | $103.01 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Gilead Sciences, INC. | $75.00 | 2025 | Trodelvy |
| Kite Pharma, INC. | $73.00 | 2024-2025 | Yescarta |
| Taiho Oncology, INC. | $72.70 | 2025 | |
| Pharmacosmos Therapeutics INC. | $64.37 | 2025 | Monoferric |
| Janssen Biotech, INC. | $58.44 | 2025 | Rybrevant, Tecvayli, Darzalex |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $57.76 | 2020-2025 | Cabometyx |
| Puma Biotechnology, INC. | $54.54 | 2025 | |
| Pfizer INC. | $52.70 | 2019-2025 | |
| Seagen INC. | $49.00 | 2022-2023 | Tukysa |
| Alexion Pharmaceuticals, INC. | $45.41 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.51 | 2025 | Ninlaro |
| Astrazeneca Pharmaceuticals LP | $42.70 | 2023-2025 | Tagrisso, Lynparza |
| Beone Medicines USA, INC. | $40.90 | 2025 | Brukinsa, Tevimbra |
| Array Biopharma INC | $36.90 | 2024-2025 | Mektovi, Braftovi, Talzenna |
| Abbvie INC. | $35.05 | 2025 | |
| Celgene Corporation | $34.50 | 2025 | Reblozyl |
| Astellas Pharma US INC | $30.96 | 2024-2025 | Padcev, Vyloy |
| Tersera Therapeutics LLC | $26.77 | 2024 | Xermelo |
| Spectrum Pharmaceuticals INC. | $25.97 | 2025 | Rolvedon |
| Beigene USA, INC. | $24.25 | 2025 | Tevimbra |
| Iovance Biotherapeutics, INC. | $23.87 | 2025 | Amtagvi |
| Janssen Pharmaceuticals, INC | $22.00 | 2024 | Rybrevant |
| Karyopharm Therapeutics INC. | $21.92 | 2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $21.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.52 | 2025 | Gilotrif |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Geron Corporation | $19.32 | 2025 | Rytelo |
| Rigel Pharmaceuticals, INC. | $18.37 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Emd Serono, INC. | $16.47 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.74 | 2024 | |
| Genentech USA, INC. | $14.53 | 2024 | Polivy, Lunsumio, Columvi |
| E.R. Squibb & Sons, L.L.C. | $14.17 | 2024 | Opdivo |
| Adc Therapeutics America, INC. | $14.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Maatouk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.